Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Market Movers
TipRanks 50 Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
MLTX
Stock Latest News
The Fly
MoonLake Immunotherapeutics participates in a conference call with Clear Street
4d ago
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Strategic Leadership Transition and Promising Clinical Progress Drive Buy Rating
4d ago
MLTX
Premium
Ratings
Promising Outlook for MoonLake Immunotherapeutics: Buy Rating Backed by Strong Position in Hidradenitis Suppurativa Treatment
7d ago
MLTX
Premium
The Fly
MoonLake initiated with a Neutral at Rothschild & Co Redburn
8d ago
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Promising Phase 3 Trials and Market Potential for Sonelokimab
13d ago
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Strategic Positioning and Promising Clinical Developments Drive Buy Rating
2M ago
MLTX
Premium
The Fly
Stat’s Feuerstein says ‘no imminent acquisition’ of MoonLake Immunotherapeutics
2M ago
MRK
MLTX
Premium
Company Announcements
MoonLake Immunotherapeutics Elects Directors at AGM
2M ago
8K
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Strong Acquisition Interest and Promising Product Pipeline Drive Buy Rating
2M ago
MLTX
Premium
The Fly
MoonLake takeover thesis reemerges after FT report, says Citi
2M ago
MRK
MLTX
Premium
The Fly
Closing Bell Movers: Credo Technology jumps 11% on earnings
2M ago
MRK
NUE
Premium
The Fly
Merck held talks to buy MoonLake for over $3B, FT reports
2M ago
MRK
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Promising Clinical Developments and Strong Financial Position Justify Buy Rating
2M ago
MLTX
Premium
The Fly
Wolfe upgrades MoonLake Immunotherapeutics ahead of sonelokimab data
3M ago
MLTX
Premium
The Fly
MoonLake upgraded to Outperform from Peer Perform at Wolfe Research
3M ago
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Buy Rating Driven by Strategic Developments and Promising Clinical Programs
3M ago
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Strong Financials and Promising Pipeline Drive Buy Rating
3M ago
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Strong Financial Position and Promising Data Releases Justify Buy Rating
3M ago
MLTX
Premium
Ratings
Promising Growth Potential and Financial Strength Drive Buy Rating for MoonLake Immunotherapeutics
3M ago
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Promising Clinical Developments and Market Opportunities Justify Buy Rating
3M ago
MLTX
Premium
The Fly
MoonLake Immunotherapeutics reports Q1 EPS (63c), consensus (74c)
3M ago
MLTX
Premium
Ratings
MoonLake Immunotherapeutics: Promising Clinical Updates and Market Potential Support Buy Rating
3M ago
MLTX
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >
You need to enable JavaScript to run this app.
